For the year ending 2026-03-31, IMVT has $957,014K in assets. $104,422K in debts. $902,110K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 902,110 | |||
| Accounts receivable | 1,133 | |||
| Prepaid expenses and other current assets | 42,763 | |||
| Income tax receivable | 2,813 | |||
| Total current assets | 948,819 | |||
| Operating lease right-of-use assets | 72 | |||
| Property and equipment, net | 443 | |||
| Other assets | 7,680 | |||
| Total assets | 957,014 | |||
| Accounts payable | 7,541 | |||
| Accrued expenses | 96,634 | |||
| Current portion of operating lease liabilities | 72 | |||
| Due to roivant sciences ltd | 175 | |||
| Total current liabilities | 104,422 | |||
| Total liabilities | 104,422 | |||
| Preferred stock-Series APreferred Stock | 0 | |||
| Preferred stock-Preferred Stock Excluding Series APreferred Stock | 0 | |||
| Common stock, par value 0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at march31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at march31, 2025 | 20 | |||
| Additional paid-in capital | 2,596,971 | |||
| Accumulated other comprehensive income | 730 | |||
| Accumulated deficit | -1,745,129 | |||
| Total stockholders equity | 852,592 | |||
| Total liabilities and stockholders equity | 957,014 | |||
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)